# Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

> **NCT03989830** · PHASE2 · UNKNOWN · sponsor: **Sun Yan** · enrollment: 53 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** second-line chemotherapy
- **DRUG:** Recombinant human endostatin

## Key facts

- **NCT ID:** NCT03989830
- **Lead sponsor:** Sun Yan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-29
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989830, "Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03989830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*